Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid
- 7 December 2007
- journal article
- research article
- Published by Wiley in Respirology
- Vol. 13 (2), 221-226
- https://doi.org/10.1111/j.1440-1843.2007.01208.x
Abstract
Background and objective: BAL is an established technique for measuring antibiotic concentrations in the epithelial lining fluid (ELF) of the bronchiolar‐alveolar regions. However, the results may not reflect concentrations in bronchial regions. Bronchoscopic microsampling (BMS) is a technique for repeated sampling of bronchial ELF. The objective of the present study was to determine the time versus concentration profile of clarithromycin and its active metabolite, 14‐hydroxy‐clarithromycin, in bronchial ELF, as determined by BMS. Methods: BMS was performed at 1, 2, 3, 5 and 10 h after a single oral administration of 200 mg clarithromycin in five healthy volunteers. BAL was performed 3 h after administration to determine clarithromycin concentrations in alveolar ELF and alveolar macrophages (AM). Results: The maximum concentration (Cmax) of clarithromycin was 0.36 ± 0.07 mg/L in serum and 1.44 ± 0.49 mg/L in bronchial ELF (P < 0.01). Cmax for 14‐hydroxy‐clarithromycin was 0.34 ± 0.13 mg/L in serum and 0.68 ± 0.34 mg/L in bronchial ELF. The area under the concentration–time curve from 0 to 10 h (AUC0‐10) for clarithromycin was 2.10 ± 0.49 mg·h/L for serum and 7.37 ± 2.07 mg·h/L for bronchial ELF (P < 0.01). The concentrations of clarithromycin in alveolar ELF and AM, 3 h after oral administration, were 4.84 ± 3.39 mg/L and 10.7 ± 8.7 mg/L, respectively. Conclusions: A single oral dose of clarithromycin produces a significantly higher Cmax and AUC0‐10 for clarithromycin in bronchial ELF than in serum, and higher concentrations in alveolar ELF and AM than in serum. BMS might be useful for measuring the pharmacokinetic profile of clarithromycin in bronchial ELF.Keywords
This publication has 30 references indexed in Scilit:
- Determination of clarithromycin in human plasma by liquid chromatography–electrospray ionization tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2007
- Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavageClinical Therapeutics, 2007
- Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumoniaCritical Care Medicine, 2005
- Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjectsJournal of Antimicrobial Chemotherapy, 2003
- Effects of AIDS and Gender on Steady-State Plasma and Intrapulmonary Ethambutol ConcentrationsAntimicrobial Agents and Chemotherapy, 2001
- The levels of clarithromycin and its 14-hydroxy metabolite in the lungEuropean Respiratory Journal, 1994
- The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administrationJournal of Antimicrobial Chemotherapy, 1994
- MEASUREMENT OF PULMONARY ERYTHROMYCIN CONCENTRATION IN PATIENTS WITH LOBAR PNEUMONIA BY MEANS OF POSITRON TOMOGRAPHYThe Lancet, 1982
- Penetration of piperacillin into bronchial mucosa and sputum.Thorax, 1981
- The mucosal epithelium of the respiratory tract in muco‐purulent bronchitis caused byHæmophilus influenzæThe Journal of Pathology and Bacteriology, 1953